Any current/future new fundraising through debt or equity?

No major new fundraising through debt or equity is planned currently. The company does not anticipate big CAPEX in the next two years except for minor debottlenecking and capitalizing existing work-in-progress (around Rs. 10 to 12 crores). Any significant fundraising may only occur if an acquisition opportunity arises which is remunerative to the company. Routine business growth will be supported by existing capacities and current financial resources without additional major debt or equity infusion.

Any current/future capex/capital investment/strategic investment?

No major CAPEX planned in the next two years. Only debottlenecking CAPEX and capital work-in-progress capitalization expected, amounting to around Rs. 10 to 12 crores. Existing CAPEX is sufficient to support the current growth rate for the next two years. New CAPEX might arise only in case of an acquisition or an unforeseen remunerative opportunity. Company is considering acquisition in the formulations space but nothing concrete or on the table currently.

Future growth expectations in sales/revenue/volumes?

The company is guiding for around 25% year-on-year growth in Pharma Intermediates as well as APIs on a consolidated basis. (Page 11) The new API manufacturing Unit #5 in Chiplun is expected to start production in Q1 FY17 with gradual scale-up, reaching good utilization and sales from Q2 FY17 onwards, focusing on Vitamin C and Folic Acid with healthy margins and significant growth opportunities. (Pages 6,11) About 20% to 25% of overall revenue is projected to come from Iodine Derivatives over the next two years, though the company is defocusing this segment due to lower margins. (Page 10) The f

Future growth expectations in earnings/operating earnings/profits/EPS?

Omkar Speciality Chemicals Ltd expects around 25% year-on-year growth in Pharma Intermediates and APIs (consolidated across segments). EBITDA margins are consistently expected around 18-19%, with some segments like Vitamin C projected at 18-20%. The new API manufacturing Unit #5 at Chiplun (starting Q1 FY17) will gradually scale up, contributing positively to sales and profits from Q2 FY17 onwards. Focus is shifting towards higher margin Specialty Intermediates and APIs, reducing reliance on low-margin Iodine derivatives, which will constitute 20-25% of revenues in the next two years. Working

Current/ Expected Orderbook/ Pending Orders?

Omkar Speciality Chemicals does not maintain a traditional order book. They operate on quarterly forecasts provided by their customers. Orders flow continuously based on these forecasts. The quarterly forecast is usually accurate with only a 10-15% variance. Customers are mainly reputed MNCs like Glaxo, Gilead Life, Abbott, Johnson & Johnson, and BASF. The forecasts provide guidance on expected sales volumes for the quarter. This system gives the company confidence in projecting business for their Intermediates segment. For APIs, demand is driven by customer product development and launch time

Omkar Speciality ChemicalsQ3 FY16Chemicals & Petrochemicals

Omkar Speciality Chemicals Q3 FY16 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3.41Market Cap: ₹7 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

0 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

The company is guiding for around 25% year-on-year growth in Pharma Intermediates as well as APIs on a consolidated basis. (Page 11)
The new API manufacturing Unit #5 in Chiplun is expected to start production in Q1 FY17 with gradual scale-up, reaching good utilization and sales from Q2 FY17 onwards, focusing on Vitamin C and Folic Acid with healthy margins and significant growth opportunities. (Pages 6,11)
About 20% to 25% of overall revenue is projected to come from Iodine Derivatives over the next two years, though the company is defocusing this segment due to lower margins. (Page 10)
The focus will be more on Specialty Intermediates, Resolving agents, and Veterinary APIs which are expected to show steep growth and better EBITDA margins. (Page 10)
The business model aims to maintain consistent EBITDA margins of around 18-19% despite raw material and forex fluctuations. (Page 6)

Margin guidance

Category 3

Omkar Speciality Chemicals Ltd expects around 25% year-on-year growth in Pharma Intermediates and APIs (consolidated across segments).
EBITDA margins are consistently expected around 18-19%, with some segments like Vitamin C projected at 18-20%.
The new API manufacturing Unit #5 at Chiplun (starting Q1 FY17) will gradually scale up, contributing positively to sales and profits from Q2 FY17 onwards.
Focus is shifting towards higher margin Specialty Intermediates and APIs, reducing reliance on low-margin Iodine derivatives, which will constitute 20-25% of revenues in the next two years.
Working capital and operational efficiencies are improving, supporting better cash flows and margins.
No major CAPEX planned, barring acquisitions; expected small CAPEX (~Rs. 10-12 crores) to enhance current capacity.
Stable EBITDA and profit growth expected despite market volatilities like forex and raw material cost fluctuations.

See what Omkar Speciality Chemicals management said on margin guidance — free account, 30 seconds.

Fundraise plans

No major new fundraising through debt or equity is planned currently.
The company does not anticipate big CAPEX in the next two years except for minor debottlenecking and capitalizing existing work-in-progress (around Rs. 10 to 12 crores).
Any significant fundraising may only occur if an acquisition opportunity arises which is remunerative to the company.
Routine business growth will be supported by existing capacities and current financial resources without additional major debt or equity infusion.

Order book

Omkar Speciality Chemicals does not maintain a traditional order book.
They operate on quarterly forecasts provided by their customers.
Orders flow continuously based on these forecasts.
The quarterly forecast is usually accurate with only a 10-15% variance.
Customers are mainly reputed MNCs like Glaxo, Gilead Life, Abbott, Johnson & Johnson, and BASF.
The forecasts provide guidance on expected sales volumes for the quarter.
This system gives the company confidence in projecting business for their Intermediates segment.
For APIs, demand is driven by customer product development and launch timelines.
The plant's first phase utilization and orders are expected to scale up gradually after commissioning in Q1 FY17.

See what Omkar Speciality Chemicals management said on order book — free account, 30 seconds.

Capex plans

No major CAPEX planned in the next two years.
Only debottlenecking CAPEX and capital work-in-progress capitalization expected, amounting to around Rs. 10 to 12 crores.
Existing CAPEX is sufficient to support the current growth rate for the next two years.
New CAPEX might arise only in case of an acquisition or an unforeseen remunerative opportunity.
Company is considering acquisition in the formulations space but nothing concrete or on the table currently.

Track Omkar Speciality Chemicals — get its next earnings analysis in your feed

How does Omkar Speciality Chemicals rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisOmkar Speciality Chemicals

Rev 2Mar 3

See where Omkar Speciality Chemicals sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Omkar Speciality Chemicals rank in Chemicals & Petrochemicals?

Compare Omkar Speciality Chemicals against every Chemicals & Petrochemicals company (Q3 FY16) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Omkar Speciality Chemicals's management said in earlier quarters

Earlier calls (3)

Others in Chemicals & Petrochemicals this season

Fineotex Chem (Q2 FY27)
Quarterly Total Income from Operations: ₹391.41 crore for Q2 FY 2026–27, up 169.14% year-on-year from ₹145.43 crore. Key results statement takeaways from Fineot
Agarwal Industrial Corporation (Q2 FY27)
Revenue from operations for the quarter ended 30.09.2026 is ₹20,857.66 Lakhs (Consolidated) and ₹20,595.73 Lakhs (Standalone). Key results statement takeaways f
Stallion India (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹13,603.15 lakhs . Key results statement takeaways from Stallion India Fluorochemicals Ltd's Q
Deepak Fertilisers & Petrochemicals Corp (Q2 FY27)
Q2 FY27 Operating Revenue: ₹3,334 Cr, up 11% YoY (Page 29 & 31) . Key investor presentation takeaways from Deepak Fertilisers & Petrochemicals Corp Ltd's Q2 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →